Pharmacokinetically modified human serum albumin based therapeutic design and development

Kazuaki Taguchi, Victor Tuan Giam Chuang, Keishi Yamasaki, Masaki Otagiri

Research output: Chapter in Book/Report/Conference proceedingChapter


Human serum albumin (HSA) is synthesized predominantly in the liver, and has an extraordinarily long circulatory half-life (~19 days). Since HSA is responsible for 80% of the colloidal osmotic pressure of plasma, the patients with hypoalbuminemia are typically given a plasma expander to increase the plasma volume. Clinically, using HSA as an extender is preferable to other options, such as dextran, hydroxylethyl starch, due to its long retention in plasma. However, the circulatory half-life of HSA is significantly- impacted by structural changes of HSA and pathological conditions. Recent scientific advances have revealed new information regarding the factors that influence the pharmacokinetic properties of HSA. In this chapter, we provide an overview of the impact of HSA structure and biotransformation upon the pharmacokinetic properties of HSA, and discuss new possibilities for the therapeutic potential of HSA based on its pharmacokinetic properties.

Original languageEnglish
Title of host publicationHuman Serum Albumin (HSA)
Subtitle of host publicationFunctional Structure, Synthesis and Therapeutic Uses
PublisherNova Science Publishers, Inc.
Number of pages21
ISBN (Electronic)9781634830157
ISBN (Print)9781634829632
Publication statusPublished - 2015 Jul 1
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'Pharmacokinetically modified human serum albumin based therapeutic design and development'. Together they form a unique fingerprint.

Cite this